Industry Research Reports
Home > Reports > Service & Software > Global Supplement CDMO Market Outlook, In‑Depth Analysis & Forecast to 2032
Global Supplement CDMO Market Outlook, In‑Depth Analysis & Forecast to 2032
Industry: Service & Software
Published Date: 2026-08-16
Pages: 166 Pages
Report ld: 6215520
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Supplement CDMO Market Size(US$)
CAGR 2026-2032
6.5%
Market Size,2032
USD 58,409
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 40,030 million
Market Forecast in 2032(Value)
US$ 58,409 million
CAGR
6.5%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Supplement CDMO market is projected to grow from US$ 37765 million in 2025 to US$ 58409 million by 2032, at a CAGR of 6.5% (2026-2032), driven by critical product segments and diverse end‑use applications.
Supplement CDMO refers to a professional organization that provides one-stop outsourcing services such as R&D, formula optimization, clinical trial support, large-scale production and packaging for health products (such as dietary supplements, functional foods, nutritional preparations, etc.). This model helps brands reduce R&D investment, accelerate product launch, and meet compliance requirements in the global market.
The outlook for the dietary supplement CDMO industry is generally positive, driven by sustained global demand for dietary supplements, functional foods, sports nutrition, healthy aging solutions, and personalized nutrition. To reduce capital investment in in-house production lines and shorten time-to-market for new products—while also navigating complex requirements such as formulation development, raw material screening, stability testing, regulatory compliance, and multi-dosage form manufacturing—brand owners are increasingly outsourcing R&D, pilot production, large-scale manufacturing, and packaging services to specialized CDMOs. Future industry growth will be increasingly concentrated in high-value-added segments—including softgels, hard capsules, tablets, powders, gummies, liquids, and complex dosage forms—alongside continued market expansion for products based on plant extracts, probiotics, proteins, vitamins and minerals, and functional active ingredients. As markets in the US, Europe, and Asia raise standards for quality traceability, GMP certification, clean-label attributes, and supply chain transparency, large-scale CDMOs possessing robust R&D capabilities, regulatory support, mass production capacity, and global supply chain networks are poised to capture greater market share; the industry is also trending toward increased specialization, economies of scale, and accelerated M&A activity.
MARKET SEGMENTATION
By Company
- Biofarma Group
- SFI Health Solutions
- TCI Bio
- Lonza
- HERMES PHARMA
- Vitaquest
- Catalent
- KD Pharma Group
- Pharma Tech Industries
- Pierre Fabre
- NutraPak USA
- American Health Formulations
- Aenova Group
- Robinson Pharma
- CAPTEK Softgel International
- Makers Nutrition
- Goerlich Pharma
- API Co., Ltd
- Kolmar BNH
- COSMAX BIO
- NOVAREX
- ORi Bionature
- Sirio Pharma
- Baihe Biotech
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Small Molecule CDMO
- Large Molecule CDMO
Segment by Application
- Sports Nutrition (Protein Powder, Amino Acids, Creatine, Electrolytes, etc.)
- Digestive Health (Probiotics, Prebiotics, Digestive Enzymes, Dietary Fiber, etc.)
- Immune Health (Vitamin C, Zinc, Elderberry, Immune Support Blends, etc.)
- Bone & Joint Health (Calcium, Glucosamine, Chondroitin, Collagen, etc.)
- Cardiovascular Health (Fish Oil, Omega-3, CoQ10, Plant Sterols, etc.)
- Beauty & Wellness (Collagen, Biotin, Beauty Gummies, etc.)
- Sleep & Mood Health (Melatonin, Magnesium, Theanine, etc.)
- Others
Segment by Category
- Capsule Supplement CDMO
- Tablet Supplement CDMO
- Powder Supplement CDMO
- Liquid Supplement CDMO
- Others
Segment by Division
- Custom Formulation
- Ready-made Formulation
- Custom + Ready-made Formulation
REPORT SCOPE
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Supplement CDMO market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
CHAPTER OUTLINE
Chapter 1: Defines the Supplement CDMO study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Supplement CDMO: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Supplement CDMO Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Small Molecule CDMO
1.2.3 Large Molecule CDMO
1.3 Market Segmentation by Product Dosage Forms
1.3.1 Global Supplement CDMO Market Size by Product Dosage Forms, 2021 vs 2025 vs 2032
1.3.2 Capsule Supplement CDMO
1.3.3 Tablet Supplement CDMO
1.3.4 Powder Supplement CDMO
1.3.5 Liquid Supplement CDMO
1.3.6 Others
1.4 Market Segmentation by Production Models
1.4.1 Global Supplement CDMO Market Size by Production Models, 2021 vs 2025 vs 2032
1.4.2 Custom Formulation
1.4.3 Ready-made Formulation
1.4.4 Custom + Ready-made Formulation
1.5 Market Segmentation by Application
1.5.1 Global Supplement CDMO Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Sports Nutrition (Protein Powder, Amino Acids, Creatine, Electrolytes, etc.)
1.5.3 Digestive Health (Probiotics, Prebiotics, Digestive Enzymes, Dietary Fiber, etc.)
1.5.4 Immune Health (Vitamin C, Zinc, Elderberry, Immune Support Blends, etc.)
1.5.5 Bone & Joint Health (Calcium, Glucosamine, Chondroitin, Collagen, etc.)
1.5.6 Cardiovascular Health (Fish Oil, Omega-3, CoQ10, Plant Sterols, etc.)
1.5.7 Beauty & Wellness (Collagen, Biotin, Beauty Gummies, etc.)
1.5.8 Sleep & Mood Health (Melatonin, Magnesium, Theanine, etc.)
1.5.9 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Executive Summary
2.1 Global Supplement CDMO Revenue Estimates and Forecasts (2021-2032)
2.2 Global Supplement CDMO Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competitive Landscape
3.1 Global Supplement CDMO Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Supplement CDMO Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Small Molecule CDMO: Market Share by Key Players
3.3.2 Large Molecule CDMO: Market Share by Key Players
3.4 Global Supplement CDMO Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Product Segmentation
4.1 Global Supplement CDMO Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Supplement CDMO Market by Product Dosage Forms
4.2.1 Global Revenue by Product Dosage Forms (2021-2032)
4.2.2 Global Revenue-Based Market Share by Product Dosage Forms (2021-2032)
4.3 Global Supplement CDMO Market by Production Models
4.3.1 Global Revenue by Production Models (2021-2032)
4.3.2 Global Revenue-Based Market Share by Production Models (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Downstream Applications and Customers
5.1 Global Supplement CDMO Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Supplement CDMO Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Supplement CDMO Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico
7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Supplement CDMO Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Supplement CDMO Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Supplement CDMO Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Supplement CDMO Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Supplement CDMO Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Supplement CDMO Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Supplement CDMO Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Supplement CDMO Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa
11 Corporate Profile
11.1 Biofarma Group
11.1.1 Biofarma Group Corporation Information
11.1.2 Biofarma Group Business Overview
11.1.3 Biofarma Group Supplement CDMO Product Features and Attributes
11.1.4 Biofarma Group Supplement CDMO Revenue and Gross Margin (2021-2026)
11.1.5 Biofarma Group Supplement CDMO Revenue by Product in 2025
11.1.6 Biofarma Group Supplement CDMO Revenue by Application in 2025
11.1.7 Biofarma Group Supplement CDMO Revenue by Geographic Area in 2025
11.1.8 Biofarma Group Supplement CDMO SWOT Analysis
11.1.9 Biofarma Group Recent Developments
11.2 SFI Health Solutions
11.2.1 SFI Health Solutions Corporation Information
11.2.2 SFI Health Solutions Business Overview
11.2.3 SFI Health Solutions Supplement CDMO Product Features and Attributes
11.2.4 SFI Health Solutions Supplement CDMO Revenue and Gross Margin (2021-2026)
11.2.5 SFI Health Solutions Supplement CDMO Revenue by Product in 2025
11.2.6 SFI Health Solutions Supplement CDMO Revenue by Application in 2025
11.2.7 SFI Health Solutions Supplement CDMO Revenue by Geographic Area in 2025
11.2.8 SFI Health Solutions Supplement CDMO SWOT Analysis
11.2.9 SFI Health Solutions Recent Developments
11.3 TCI Bio
11.3.1 TCI Bio Corporation Information
11.3.2 TCI Bio Business Overview
11.3.3 TCI Bio Supplement CDMO Product Features and Attributes
11.3.4 TCI Bio Supplement CDMO Revenue and Gross Margin (2021-2026)
11.3.5 TCI Bio Supplement CDMO Revenue by Product in 2025
11.3.6 TCI Bio Supplement CDMO Revenue by Application in 2025
11.3.7 TCI Bio Supplement CDMO Revenue by Geographic Area in 2025
11.3.8 TCI Bio Supplement CDMO SWOT Analysis
11.3.9 TCI Bio Recent Developments
11.4 Lonza
11.4.1 Lonza Corporation Information
11.4.2 Lonza Business Overview
11.4.3 Lonza Supplement CDMO Product Features and Attributes
11.4.4 Lonza Supplement CDMO Revenue and Gross Margin (2021-2026)
11.4.5 Lonza Supplement CDMO Revenue by Product in 2025
11.4.6 Lonza Supplement CDMO Revenue by Application in 2025
11.4.7 Lonza Supplement CDMO Revenue by Geographic Area in 2025
11.4.8 Lonza Supplement CDMO SWOT Analysis
11.4.9 Lonza Recent Developments
11.5 HERMES PHARMA
11.5.1 HERMES PHARMA Corporation Information
11.5.2 HERMES PHARMA Business Overview
11.5.3 HERMES PHARMA Supplement CDMO Product Features and Attributes
11.5.4 HERMES PHARMA Supplement CDMO Revenue and Gross Margin (2021-2026)
11.5.5 HERMES PHARMA Supplement CDMO Revenue by Product in 2025
11.5.6 HERMES PHARMA Supplement CDMO Revenue by Application in 2025
11.5.7 HERMES PHARMA Supplement CDMO Revenue by Geographic Area in 2025
11.5.8 HERMES PHARMA Supplement CDMO SWOT Analysis
11.5.9 HERMES PHARMA Recent Developments
11.6 Vitaquest
11.6.1 Vitaquest Corporation Information
11.6.2 Vitaquest Business Overview
11.6.3 Vitaquest Supplement CDMO Product Features and Attributes
11.6.4 Vitaquest Supplement CDMO Revenue and Gross Margin (2021-2026)
11.6.5 Vitaquest Recent Developments
11.7 Catalent
11.7.1 Catalent Corporation Information
11.7.2 Catalent Business Overview
11.7.3 Catalent Supplement CDMO Product Features and Attributes
11.7.4 Catalent Supplement CDMO Revenue and Gross Margin (2021-2026)
11.7.5 Catalent Recent Developments
11.8 KD Pharma Group
11.8.1 KD Pharma Group Corporation Information
11.8.2 KD Pharma Group Business Overview
11.8.3 KD Pharma Group Supplement CDMO Product Features and Attributes
11.8.4 KD Pharma Group Supplement CDMO Revenue and Gross Margin (2021-2026)
11.8.5 KD Pharma Group Recent Developments
11.9 Pharma Tech Industries
11.9.1 Pharma Tech Industries Corporation Information
11.9.2 Pharma Tech Industries Business Overview
11.9.3 Pharma Tech Industries Supplement CDMO Product Features and Attributes
11.9.4 Pharma Tech Industries Supplement CDMO Revenue and Gross Margin (2021-2026)
11.9.5 Pharma Tech Industries Recent Developments
11.10 Pierre Fabre
11.10.1 Pierre Fabre Corporation Information
11.10.2 Pierre Fabre Business Overview
11.10.3 Pierre Fabre Supplement CDMO Product Features and Attributes
11.10.4 Pierre Fabre Supplement CDMO Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 NutraPak USA
11.11.1 NutraPak USA Corporation Information
11.11.2 NutraPak USA Business Overview
11.11.3 NutraPak USA Supplement CDMO Product Features and Attributes
11.11.4 NutraPak USA Supplement CDMO Revenue and Gross Margin (2021-2026)
11.11.5 NutraPak USA Recent Developments
11.12 American Health Formulations
11.12.1 American Health Formulations Corporation Information
11.12.2 American Health Formulations Business Overview
11.12.3 American Health Formulations Supplement CDMO Product Features and Attributes
11.12.4 American Health Formulations Supplement CDMO Revenue and Gross Margin (2021-2026)
11.12.5 American Health Formulations Recent Developments
11.13 Aenova Group
11.13.1 Aenova Group Corporation Information
11.13.2 Aenova Group Business Overview
11.13.3 Aenova Group Supplement CDMO Product Features and Attributes
11.13.4 Aenova Group Supplement CDMO Revenue and Gross Margin (2021-2026)
11.13.5 Aenova Group Recent Developments
11.14 Robinson Pharma
11.14.1 Robinson Pharma Corporation Information
11.14.2 Robinson Pharma Business Overview
11.14.3 Robinson Pharma Supplement CDMO Product Features and Attributes
11.14.4 Robinson Pharma Supplement CDMO Revenue and Gross Margin (2021-2026)
11.14.5 Robinson Pharma Recent Developments
11.15 CAPTEK Softgel International
11.15.1 CAPTEK Softgel International Corporation Information
11.15.2 CAPTEK Softgel International Business Overview
11.15.3 CAPTEK Softgel International Supplement CDMO Product Features and Attributes
11.15.4 CAPTEK Softgel International Supplement CDMO Revenue and Gross Margin (2021-2026)
11.15.5 CAPTEK Softgel International Recent Developments
11.16 Makers Nutrition
11.16.1 Makers Nutrition Corporation Information
11.16.2 Makers Nutrition Business Overview
11.16.3 Makers Nutrition Supplement CDMO Product Features and Attributes
11.16.4 Makers Nutrition Supplement CDMO Revenue and Gross Margin (2021-2026)
11.16.5 Makers Nutrition Recent Developments
11.17 Goerlich Pharma
11.17.1 Goerlich Pharma Corporation Information
11.17.2 Goerlich Pharma Business Overview
11.17.3 Goerlich Pharma Supplement CDMO Product Features and Attributes
11.17.4 Goerlich Pharma Supplement CDMO Revenue and Gross Margin (2021-2026)
11.17.5 Goerlich Pharma Recent Developments
11.18 API Co., Ltd
11.18.1 API Co., Ltd Corporation Information
11.18.2 API Co., Ltd Business Overview
11.18.3 API Co., Ltd Supplement CDMO Product Features and Attributes
11.18.4 API Co., Ltd Supplement CDMO Revenue and Gross Margin (2021-2026)
11.18.5 API Co., Ltd Recent Developments
11.19 Kolmar BNH
11.19.1 Kolmar BNH Corporation Information
11.19.2 Kolmar BNH Business Overview
11.19.3 Kolmar BNH Supplement CDMO Product Features and Attributes
11.19.4 Kolmar BNH Supplement CDMO Revenue and Gross Margin (2021-2026)
11.19.5 Kolmar BNH Recent Developments
11.20 COSMAX BIO
11.20.1 COSMAX BIO Corporation Information
11.20.2 COSMAX BIO Business Overview
11.20.3 COSMAX BIO Supplement CDMO Product Features and Attributes
11.20.4 COSMAX BIO Supplement CDMO Revenue and Gross Margin (2021-2026)
11.20.5 COSMAX BIO Recent Developments
11.21 NOVAREX
11.21.1 NOVAREX Corporation Information
11.21.2 NOVAREX Business Overview
11.21.3 NOVAREX Supplement CDMO Product Features and Attributes
11.21.4 NOVAREX Supplement CDMO Revenue and Gross Margin (2021-2026)
11.21.5 NOVAREX Recent Developments
11.22 ORi Bionature
11.22.1 ORi Bionature Corporation Information
11.22.2 ORi Bionature Business Overview
11.22.3 ORi Bionature Supplement CDMO Product Features and Attributes
11.22.4 ORi Bionature Supplement CDMO Revenue and Gross Margin (2021-2026)
11.22.5 ORi Bionature Recent Developments
11.23 Sirio Pharma
11.23.1 Sirio Pharma Corporation Information
11.23.2 Sirio Pharma Business Overview
11.23.3 Sirio Pharma Supplement CDMO Product Features and Attributes
11.23.4 Sirio Pharma Supplement CDMO Revenue and Gross Margin (2021-2026)
11.23.5 Sirio Pharma Recent Developments
11.24 Baihe Biotech
11.24.1 Baihe Biotech Corporation Information
11.24.2 Baihe Biotech Business Overview
11.24.3 Baihe Biotech Supplement CDMO Product Features and Attributes
11.24.4 Baihe Biotech Supplement CDMO Revenue and Gross Margin (2021-2026)
11.24.5 Baihe Biotech Recent Developments
12 Supplement CDMO Value Chain and Ecosystem Analysis
12.1 Supplement CDMO Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Supplement CDMO Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Supplement CDMO Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Supplement CDMO Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Supplement CDMO Market Size Growth Rate by Product Dosage Forms, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Supplement CDMO Market Size Growth Rate by Production Models, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Supplement CDMO Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Supplement CDMO Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Supplement CDMO Revenue by Region (US$ Million), 2021-2026
Table 7. Global Supplement CDMO Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Supplement CDMO Revenue by Players (US$ Million), 2021-2026
Table 10. Global Supplement CDMO Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Supplement CDMO Revenue, 2025
Table 13. Global Supplement CDMO Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Supplement CDMO Companies Headquarters
Table 15. Global Supplement CDMO Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Supplement CDMO Revenue by Type (US$ Million), 2021-2026
Table 19. Global Supplement CDMO Revenue by Type (US$ Million), 2027-2032
Table 20. Global Supplement CDMO Revenue by Product Dosage Forms (US$ Million), 2021-2026
Table 21. Global Supplement CDMO Revenue by Product Dosage Forms (US$ Million), 2027-2032
Table 22. Global Supplement CDMO Revenue by Production Models (US$ Million), 2021-2026
Table 23. Global Supplement CDMO Revenue by Production Models (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Supplement CDMO Revenue by Application (US$ Million), 2021-2026
Table 26. Global Supplement CDMO Revenue by Application (US$ Million), 2027-2032
Table 27. Supplement CDMO High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Supplement CDMO Growth Accelerators and Market Barriers
Table 31. North America Supplement CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Supplement CDMO Growth Accelerators and Market Barriers
Table 33. Europe Supplement CDMO Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Supplement CDMO Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Supplement CDMO Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Supplement CDMO Investment Opportunities and Key Challenges
Table 37. Central and South America Supplement CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Supplement CDMO Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Supplement CDMO Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Biofarma Group Corporation Information
Table 41. Biofarma Group Description and Major Businesses
Table 42. Biofarma Group Product Features and Attributes
Table 43. Biofarma Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Biofarma Group Revenue Proportion by Product in 2025
Table 45. Biofarma Group Revenue Proportion by Application in 2025
Table 46. Biofarma Group Revenue Proportion by Geographic Area in 2025
Table 47. Biofarma Group Supplement CDMO SWOT Analysis
Table 48. Biofarma Group Recent Developments
Table 49. SFI Health Solutions Corporation Information
Table 50. SFI Health Solutions Description and Major Businesses
Table 51. SFI Health Solutions Product Features and Attributes
Table 52. SFI Health Solutions Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. SFI Health Solutions Revenue Proportion by Product in 2025
Table 54. SFI Health Solutions Revenue Proportion by Application in 2025
Table 55. SFI Health Solutions Revenue Proportion by Geographic Area in 2025
Table 56. SFI Health Solutions Supplement CDMO SWOT Analysis
Table 57. SFI Health Solutions Recent Developments
Table 58. TCI Bio Corporation Information
Table 59. TCI Bio Description and Major Businesses
Table 60. TCI Bio Product Features and Attributes
Table 61. TCI Bio Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. TCI Bio Revenue Proportion by Product in 2025
Table 63. TCI Bio Revenue Proportion by Application in 2025
Table 64. TCI Bio Revenue Proportion by Geographic Area in 2025
Table 65. TCI Bio Supplement CDMO SWOT Analysis
Table 66. TCI Bio Recent Developments
Table 67. Lonza Corporation Information
Table 68. Lonza Description and Major Businesses
Table 69. Lonza Product Features and Attributes
Table 70. Lonza Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Lonza Revenue Proportion by Product in 2025
Table 72. Lonza Revenue Proportion by Application in 2025
Table 73. Lonza Revenue Proportion by Geographic Area in 2025
Table 74. Lonza Supplement CDMO SWOT Analysis
Table 75. Lonza Recent Developments
Table 76. HERMES PHARMA Corporation Information
Table 77. HERMES PHARMA Description and Major Businesses
Table 78. HERMES PHARMA Product Features and Attributes
Table 79. HERMES PHARMA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. HERMES PHARMA Revenue Proportion by Product in 2025
Table 81. HERMES PHARMA Revenue Proportion by Application in 2025
Table 82. HERMES PHARMA Revenue Proportion by Geographic Area in 2025
Table 83. HERMES PHARMA Supplement CDMO SWOT Analysis
Table 84. HERMES PHARMA Recent Developments
Table 85. Vitaquest Corporation Information
Table 86. Vitaquest Description and Major Businesses
Table 87. Vitaquest Product Features and Attributes
Table 88. Vitaquest Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Vitaquest Recent Developments
Table 90. Catalent Corporation Information
Table 91. Catalent Description and Major Businesses
Table 92. Catalent Product Features and Attributes
Table 93. Catalent Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. Catalent Recent Developments
Table 95. KD Pharma Group Corporation Information
Table 96. KD Pharma Group Description and Major Businesses
Table 97. KD Pharma Group Product Features and Attributes
Table 98. KD Pharma Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. KD Pharma Group Recent Developments
Table 100. Pharma Tech Industries Corporation Information
Table 101. Pharma Tech Industries Description and Major Businesses
Table 102. Pharma Tech Industries Product Features and Attributes
Table 103. Pharma Tech Industries Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Pharma Tech Industries Recent Developments
Table 105. Pierre Fabre Corporation Information
Table 106. Pierre Fabre Description and Major Businesses
Table 107. Pierre Fabre Product Features and Attributes
Table 108. Pierre Fabre Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. Pierre Fabre Recent Developments
Table 110. NutraPak USA Corporation Information
Table 111. NutraPak USA Description and Major Businesses
Table 112. NutraPak USA Product Features and Attributes
Table 113. NutraPak USA Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. NutraPak USA Recent Developments
Table 115. American Health Formulations Corporation Information
Table 116. American Health Formulations Description and Major Businesses
Table 117. American Health Formulations Product Features and Attributes
Table 118. American Health Formulations Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. American Health Formulations Recent Developments
Table 120. Aenova Group Corporation Information
Table 121. Aenova Group Description and Major Businesses
Table 122. Aenova Group Product Features and Attributes
Table 123. Aenova Group Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Aenova Group Recent Developments
Table 125. Robinson Pharma Corporation Information
Table 126. Robinson Pharma Description and Major Businesses
Table 127. Robinson Pharma Product Features and Attributes
Table 128. Robinson Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. Robinson Pharma Recent Developments
Table 130. CAPTEK Softgel International Corporation Information
Table 131. CAPTEK Softgel International Description and Major Businesses
Table 132. CAPTEK Softgel International Product Features and Attributes
Table 133. CAPTEK Softgel International Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. CAPTEK Softgel International Recent Developments
Table 135. Makers Nutrition Corporation Information
Table 136. Makers Nutrition Description and Major Businesses
Table 137. Makers Nutrition Product Features and Attributes
Table 138. Makers Nutrition Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Makers Nutrition Recent Developments
Table 140. Goerlich Pharma Corporation Information
Table 141. Goerlich Pharma Description and Major Businesses
Table 142. Goerlich Pharma Product Features and Attributes
Table 143. Goerlich Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Goerlich Pharma Recent Developments
Table 145. API Co., Ltd Corporation Information
Table 146. API Co., Ltd Description and Major Businesses
Table 147. API Co., Ltd Product Features and Attributes
Table 148. API Co., Ltd Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. API Co., Ltd Recent Developments
Table 150. Kolmar BNH Corporation Information
Table 151. Kolmar BNH Description and Major Businesses
Table 152. Kolmar BNH Product Features and Attributes
Table 153. Kolmar BNH Revenue (US$ Million) and Gross Margin (2021-2026)
Table 154. Kolmar BNH Recent Developments
Table 155. COSMAX BIO Corporation Information
Table 156. COSMAX BIO Description and Major Businesses
Table 157. COSMAX BIO Product Features and Attributes
Table 158. COSMAX BIO Revenue (US$ Million) and Gross Margin (2021-2026)
Table 159. COSMAX BIO Recent Developments
Table 160. NOVAREX Corporation Information
Table 161. NOVAREX Description and Major Businesses
Table 162. NOVAREX Product Features and Attributes
Table 163. NOVAREX Revenue (US$ Million) and Gross Margin (2021-2026)
Table 164. NOVAREX Recent Developments
Table 165. ORi Bionature Corporation Information
Table 166. ORi Bionature Description and Major Businesses
Table 167. ORi Bionature Product Features and Attributes
Table 168. ORi Bionature Revenue (US$ Million) and Gross Margin (2021-2026)
Table 169. ORi Bionature Recent Developments
Table 170. Sirio Pharma Corporation Information
Table 171. Sirio Pharma Description and Major Businesses
Table 172. Sirio Pharma Product Features and Attributes
Table 173. Sirio Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 174. Sirio Pharma Recent Developments
Table 175. Baihe Biotech Corporation Information
Table 176. Baihe Biotech Description and Major Businesses
Table 177. Baihe Biotech Product Features and Attributes
Table 178. Baihe Biotech Revenue (US$ Million) and Gross Margin (2021-2026)
Table 179. Baihe Biotech Recent Developments
Table 180. Technologies, Platforms and Infrastructure
Table 181. Distributors List
Table 182. Market Trends and Market Evolution
Table 183. Market Drivers and Opportunities
Table 184. Market Challenges, Risks, and Restraints
Table 185. Research Programs/Design for This Report
Table 186. Key Data Information from Secondary Sources
Table 187. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Supplement CDMO Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Small Molecule CDMO Product Picture
Figure 3. Large Molecule CDMO Product Picture
Figure 4. Global Supplement CDMO Market Size Growth Rate by Product Dosage Forms, 2021 vs 2025 vs 2032 (US$ Million)
Figure 5. Capsule Supplement CDMO Product Picture
Figure 6. Tablet Supplement CDMO Product Picture
Figure 7. Powder Supplement CDMO Product Picture
Figure 8. Liquid Supplement CDMO Product Picture
Figure 9. Others Product Picture
Figure 10. Global Supplement CDMO Market Size Growth Rate by Production Models, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Custom Formulation Product Picture
Figure 12. Ready-made Formulation Product Picture
Figure 13. Custom + Ready-made Formulation Product Picture
Figure 14. Global Supplement CDMO Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Sports Nutrition (Protein Powder, Amino Acids, Creatine, Electrolytes, etc.)
Figure 16. Digestive Health (Probiotics, Prebiotics, Digestive Enzymes, Dietary Fiber, etc.)
Figure 17. Immune Health (Vitamin C, Zinc, Elderberry, Immune Support Blends, etc.)
Figure 18. Bone & Joint Health (Calcium, Glucosamine, Chondroitin, Collagen, etc.)
Figure 19. Cardiovascular Health (Fish Oil, Omega-3, CoQ10, Plant Sterols, etc.)
Figure 20. Beauty & Wellness (Collagen, Biotin, Beauty Gummies, etc.)
Figure 21. Sleep & Mood Health (Melatonin, Magnesium, Theanine, etc.)
Figure 22. Others
Figure 23. Supplement CDMO Report Years Considered
Figure 24. Global Supplement CDMO Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 25. Global Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 26. Global Supplement CDMO Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 27. Global Supplement CDMO Revenue-Based Market Share by Region (2021-2032)
Figure 28. Global Supplement CDMO Revenue-Based Market Share Ranking (2025)
Figure 29. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 30. Small Molecule CDMO Revenue-Based Market Share by Player in 2025
Figure 31. Large Molecule CDMO Revenue-Based Market Share by Player in 2025
Figure 32. Global Supplement CDMO Revenue-Based Market Share by Type (2021-2032)
Figure 33. Global Supplement CDMO Revenue-Based Market Share by Product Dosage Forms (2021-2032)
Figure 34. Global Supplement CDMO Revenue-Based Market Share by Production Models (2021-2032)
Figure 35. Global Supplement CDMO Revenue-Based Market Share by Application (2021-2032)
Figure 36. North America Supplement CDMO Revenue YoY (US$ Million), 2021-2032
Figure 37. North America Top 5 Players Supplement CDMO Revenue (US$ Million) in 2025
Figure 38. North America Supplement CDMO Revenue (US$ Million) by Application (2021-2032)
Figure 39. US Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 40. Canada Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 41. Mexico Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 42. Europe Supplement CDMO Revenue YoY (US$ Million), 2021-2032
Figure 43. Europe Top 5 Players Supplement CDMO Revenue (US$ Million) in 2025
Figure 44. Europe Supplement CDMO Revenue (US$ Million) by Application (2021-2032)
Figure 45. Germany Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 46. France Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 47. U.K. Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 48. Italy Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 49. Russia Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 50. Asia-Pacific Supplement CDMO Revenue YoY (US$ Million), 2021-2032
Figure 51. Asia-Pacific Top 8 Players Supplement CDMO Revenue (US$ Million) in 2025
Figure 52. Asia-Pacific Supplement CDMO Revenue (US$ Million) by Application (2021-2032)
Figure 53. Indonesia Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 54. Japan Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 55. South Korea Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 56. Australia Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 57. India Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 58. Indonesia Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 59. Vietnam Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 60. Malaysia Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 61. Philippines Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 62. Singapore Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 63. Central and South America Supplement CDMO Revenue YoY (US$ Million), 2021-2032
Figure 64. Central and South America Top 5 Players Supplement CDMO Revenue (US$ Million) in 2025
Figure 65. Central and South America Supplement CDMO Revenue (US$ Million) by Application (2021-2032)
Figure 66. Brazil Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 67. Argentina Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 68. Middle East and Africa Supplement CDMO Revenue YoY (US$ Million), 2021-2032
Figure 69. Middle East and Africa Top 5 Players Supplement CDMO Revenue (US$ Million) in 2025
Figure 70. Middle East and Africa Supplement CDMO Revenue (US$ Million) by Application (2021-2032)
Figure 71. GCC Countries Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 72. Israel Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 73. Egypt Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 74. South Africa Supplement CDMO Revenue (US$ Million), 2021-2032
Figure 75. Supplement CDMO Value Chain Mapping
Figure 76. Channels of Distribution (Direct Vs Distribution)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What was the global market size of Supplement CDMO in 2026?
The global market size of Supplement CDMO in 2026 was 40030 Million USD.
What was the global market size of Supplement CDMO in 2032?
What is the annual compound growth rate of the global Supplement CDMO market size from 2026 to 2032?
Which companies rank high in the global Supplement CDMO market?
Which region is expected to have the highest market share?
Related Reports
Global Supplement CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Supplement CDMO market size was US$ 37765 million in 2025 and is forecast to reach a readjusted size of US$ 58409 million by 2032 with a CAGR of 6.5% during the forecast period 2026-2032.
Published Date: 2026-08-16
Pages: 156
USD 4250.00
(Single User License)
Supplement CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Supplement CDMO was estimated to be worth US$ 37765 million in 2025 and is projected to reach US$ 58409 million, growing at a CAGR of 6.5% from 2026 to 2032.
Published Date: 2026-08-16
Pages: 142
USD 3950.00
(Single User License)
Global Supplement CDMO Market Research Report 2026
The global Supplement CDMO market was valued at US$ 37765 million in 2025 and is anticipated to reach US$ 58409 million by 2032, at a CAGR of 6.5% from 2026 to 2032.
Published Date: 2026-08-16
Pages: 152
USD 2900.00
(Single User License)
Global Supplement CDMO Market Research Report 2025
The global market for Supplement CDMO was valued at US$ 12010 million in the year 2024 and is projected to reach a revised size of US$ 18660 million by 2031, growing at a CAGR of 6.5% during the forecast period.
Published Date: 2025-06-06
Pages: 83
USD 2900.00
(Single User License)
Supplement CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Supplement CDMO was estimated to be worth US$ 12010 million in 2024 and is forecast to a readjusted size of US$ 18660 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.
Published Date: 2025-06-06
Pages: 109
USD 3950.00
(Single User License)
Global Supplement CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Supplement CDMO market size was US$ 12010 million in 2024 and is forecast to a readjusted size of US$ 18660 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.
Published Date: 2025-06-06
Pages: 93
USD 4250.00
(Single User License)
Global Supplement CDMO Market Insights, Forecast to 2031
The global Supplement CDMO market is projected to grow from US$ 12790 million in 2025 to US$ 18660 million by 2031, at a Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period.
Published Date: 2025-06-06
Pages: 131
USD 4900.00
(Single User License)
Global Supplement CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Supplement CDMO market size was US$ 37765 million in 2025 and is forecast to reach a readjusted size of US$ 58409 million by 2032 with a CAGR of 6.5% during the forecast period 2026-2032.
Published: 2026-08-16
Pages: 156
USD 4250.00 (Single User License)Supplement CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Supplement CDMO was estimated to be worth US$ 37765 million in 2025 and is projected to reach US$ 58409 million, growing at a CAGR of 6.5% from 2026 to 2032.
Published: 2026-08-16
Pages: 142
USD 3950.00 (Single User License)Global Supplement CDMO Market Research Report 2026
The global Supplement CDMO market was valued at US$ 37765 million in 2025 and is anticipated to reach US$ 58409 million by 2032, at a CAGR of 6.5% from 2026 to 2032.
Published: 2026-08-16
Pages: 152
USD 2900.00 (Single User License)Global Supplement CDMO Market Research Report 2025
The global market for Supplement CDMO was valued at US$ 12010 million in the year 2024 and is projected to reach a revised size of US$ 18660 million by 2031, growing at a CAGR of 6.5% during the forecast period.
Published: 2025-06-06
Pages: 83
USD 2900.00 (Single User License)Supplement CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Supplement CDMO was estimated to be worth US$ 12010 million in 2024 and is forecast to a readjusted size of US$ 18660 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.
Published: 2025-06-06
Pages: 109
USD 3950.00 (Single User License)Global Supplement CDMO Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Supplement CDMO market size was US$ 12010 million in 2024 and is forecast to a readjusted size of US$ 18660 million by 2031 with a CAGR of 6.5% during the forecast period 2025-2031.
Published: 2025-06-06
Pages: 93
USD 4250.00 (Single User License)Global Supplement CDMO Market Insights, Forecast to 2031
The global Supplement CDMO market is projected to grow from US$ 12790 million in 2025 to US$ 18660 million by 2031, at a Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period.
Published: 2025-06-06
Pages: 131
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
REPORT SCOPE
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now